Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% based on its latest 2019Q2 regulatory filing with the SEC. Cabot Wealth Management Inc bought 5,317 shares as the company’s stock declined 2.22% . The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. Cabot Wealth Management Inc who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be bullish on the $4.15B market cap company. The stock decreased 0.07% or $0.1 during the last trading session, reaching $136.22. About 406,943 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has risen 21.75% since November 4, 2018 and is uptrending. It has outperformed by 21.75% the S&P500. Some Historical GWPH News: 19/04/2018 – GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT…; 16/05/2018 – GW PHARMACEUTICALS REPORTS PROGRESS IN CANNABIDIOL ORAL STUDY; 17/04/2018 – GW cannabis-derived epilepsy drug gets positive FDA staff review; 06/04/2018 – Isodiol International Inc. Announces Letter of Intent to Supply 99.5%+ Pharma-Grade Cannabidiol to Agrima Botanicals; 19/04/2018 – The medication, which is manufactured by GW Pharmaceuticals, is used in the treatment of seizures associated with childhood epilepsy; 16/05/2018 – GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences Announce Publication in The New England Journal of Medicine of a P; 14/05/2018 – Peak Health Announces Filing of Patent Applications for testing the “Bioactivity” of the Cannabidiol (CBD) molecule and publica; 19/04/2018 – GW PHARMACEUTICALS PLC – PDUFA GOAL DATE FOR COMPLETION OF NDA REVIEW OF THE CANNABIDIOL ORAL SOLUTION EPIDIOLEX IS JUNE 27, 2018; 19/04/2018 – GW Pharma’s Drug Could Become First FDA-Approved Drug Derived From Cannabis; 19/04/2018 – GW Pharma walks away from adcomm with unanimous support for anti-seizure med. An OK shouldn’t take long now $GWPH
Cabot Wealth Management Inc, which manages about $552.75M and $474.10M US Long portfolio, decreased its stake in Idexx Labs Inc (NASDAQ:IDXX) by 4,604 shares to 4,305 shares, valued at $1.19M in 2019Q2, according to the filing. It also reduced its holding in Novo (NYSE:NVO) by 5,922 shares in the quarter, leaving it with 107,482 shares, and cut its stake in Schwab Strategic Tr (SCHX).
More notable recent GW Pharmaceuticals plc (NASDAQ:GWPH) news were published by: Prnewswire.com which released: “The Psilocybin Mushroom Story Could be the Next Big Investment Boom – PRNewswire” on October 10, 2019, also Finance.Yahoo.com with their article: “GW Pharmaceuticals PLC (GWPH) Outpaces Stock Market Gains: What You Should Know – Yahoo Finance” published on October 24, 2019, Streetinsider.com published: “Needham & Company Starts GW Pharma (GWPH) at Buy – StreetInsider.com” on October 21, 2019. More interesting news about GW Pharmaceuticals plc (NASDAQ:GWPH) were released by: Seekingalpha.com and their article: “GW Pharma Earnings Present Buying Opportunity – Seeking Alpha” published on October 24, 2019 as well as Nasdaq.com‘s news article titled: “Morgan Stanley: 2 European Stocks to Overthrow the US Market Dominance – Nasdaq” with publication date: October 23, 2019.
